GHRP-6 and ipamorelin: the human record counted

Both compounds on this page — GHRP-6 and ipamorelin — are sold on one shared claim: raise growth hormone, and the rest follows. The interesting part is not that the evidence is thin. It is where it lives.

What the index holds

"GHRP-6"[tiab] returns 638 records on PubMed and ipamorelin[tiab] returns 50 (re-run 5 October 2026, every term tagged to title and abstract). Filtering each by (randomized[tiab] OR randomised[tiab] OR trial[tiab] OR patients[tiab] OR placebo[tiab] OR “healthy volunteers”[tiab]) leaves 113 and 10. Both queries can be pasted back into PubMed to check; the counts move as records are added.

GHRP-6 in people is a diagnostic reagent

The consistent finding across the human literature is that GHRP-6 ended up as a stimulant in a GH stimulation test. In children of short stature and adults with diagnosed growth hormone deficiency, the GH response to GHRP-6 was lower than in normal children, but with “a considerable degree of overlap” between the two groups on an individual basis — the paper’s own words (Pombo et al., PMID 8887178). A companion review put it more plainly: there is “a large variability in the stimulatory action of GHRH contrasted with the reproducibility of action of GHRPs” (Popovic et al., PMID 8887173).

The metabolic context matters. In 16 women with polycystic ovary syndrome and 22 controls, GHRP-6 90 µg intravenously produced no difference in GH peak or area under the curve between obese and non-obese PCOS groups, while GHRH alone did separate them (Micić et al., PMID 8959075). Current guidance treats the insulin tolerance test as the reference standard, with a GH peak below 3 µg/l defining severe deficiency, and names GHRH-plus-arginine or GHRP-6 as reliable alternatives with defined cut-offs that are independent of age and gender — while warning the response is negatively correlated with body mass index, so cut-offs must match lean, overweight and obese subjects (Corneli et al., PMID 17429591; Abs, PMID 12670294).

So the human use of GHRP-6 the literature supports is measuring a pituitary reserve — not what the product page implies.

Two human records where GHRP-6 was given for its hormone effect

One is a retrospective chart review. Of 105 men on testosterone prescribed 100 µg of GHRP-6, GHRP-2 or sermorelin three times daily, only 14 met strict inclusion criteria. Mean age was 33.2 (SD 2.9) years; treatment ran 134 (SD 88) days on average; IGF-1 rose from 159.5 (SD 26.7) to 239.0 (SD 54.6) ng/mL (p < .0001). Three of the 14 were on an aromatase inhibitor or tamoxifen beforehand and four more received one during treatment. The endpoint evaluated was a serum marker (Sigalos et al., PMID 28830317). Lean mass and fat loss are named in that paper as what the men were after; they are not the outcomes it reports.

The second is an acute metabolic challenge. Ten healthy non-obese men were studied under two conditions, three days of fasting and the fed state, five men each. In the fed arm, GHRP-6 1 µg/kg under GH-receptor blockade by pegvisomant caused an increase in serum insulin — the abstract prints 10.3 (SD 2.1) against 81.3 (SD 25.4) mU/L, p < 0.001 — and glucose, 4.2 (SD 0.3) against 6.0 (SD 0.6) mmol/L, p < 0.05. The same infusion changed nothing without the blockade or during fasting (Muller et al., PMID 11158013). The authors’ reading of their data is the part worth keeping: GHRP-6-mediated metabolic changes “are characterized by an increase in fat mass and a decrease in lean body mass.”

Why ipamorelin exists at all

Ipamorelin was built to fix a problem with its class. In conscious swine, GHRP-2 and GHRP-6 both raised plasma ACTH and cortisol; ipamorelin did not, and that separation held even at more than 200-fold the ED50 for GH release. None of the secretagogues tested moved FSH, LH, prolactin or TSH. The authors called it the first GHRP-receptor agonist with GH-release selectivity similar to GHRH (Raun et al., PMID 9849822). The pharmacokinetics were worked out in rats: ipamorelin’s systemic clearance ran 5-fold lower than GHRP-6’s, went mainly to urine where GHRP-6 went to bile, and gave roughly 20 % bioavailability intranasally against about 50 % for GHRP-2 (Johansen et al., PMID 9879640).

The two human ipamorelin records

In healthy male volunteers, ipamorelin reliably moved growth hormone. An escalating design with eight subjects per level and five infusion rates gave a terminal half-life of 2 hours, clearance of 0.078 L/h/kg, a GH peak at 0.67 hours at every level, and a half-maximal concentration of 214 nmol/L. Inter-individual variability was larger for the hormone response than for the pharmacokinetics (Gobburu et al., PMID 10496658) — and, on its own, an outcome.

The therapeutic trial came later and did not succeed. In a multicentre, double-blind, placebo-controlled phase 2 study after bowel resection (NCT00672074), 117 patients were enrolled and 114 formed the safety and modified intent-to-treat populations. Median time from first administration to tolerance of a solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, p = 0.15. Treatment-emergent adverse events were 87.5 % and 94.8 % respectively. The authors’ conclusion: well tolerated, with “no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses” (Beck et al., PMID 25331030).

The animal work is substantial, and it runs the other way on body fat

In adult female rats given methylprednisolone for three months, adding ipamorelin significantly increased maximum tetanic tension of the calf muscle and raised the periosteal bone formation rate four-fold against glucocorticoid alone (Andersen et al., PMID 11735244) — in rats, under a steroid-damage model. GHRP-6 has its own protective effect in rats given doxorubicin, preserving left-ventricular systolic function (Berlanga-Acosta et al., PMID 38873418), and pituitary cells in vitro release GH in response to GHRP-6 without the rise in intracellular cAMP that GHRP-2 produces (Wu et al., PMID 8699133).

The fat data point the other way. In mice, two weeks of twice-daily secretagogue treatment with ipamorelin or GHRP-6 increased relative body fat on dual-energy X-ray absorptiometry, and raised food intake and leptin, while growth hormone itself reduced relative fat mass in the deficient animals only (Lall et al., PMID 11162489). In diabetic rats, insulin improved hyperglycaemia and GHRP-6 did not; together they increased weight gain and visceral fat (Granado et al., PMID 20219977). A secretagogue is a hormone-axis drug, not a fat-loss drug.

One more trap: [D-Lys3]-GHRP-6 is not GHRP-6. It is a selective receptor antagonist, widely employed as a blocking tool, and the muscle-autophagy findings attached to it (Yu et al., PMID 25450862) say nothing about the agonist.

What a proper absence search returns

Searched 5 October 2026, every term tagged. "GHRP-6"[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "fat mass"[tiab]) returns 8: two reviews (PMIDs 32257855, 10193871), four rodent or mouse experiments, one of them on the antagonist rather than the agonist (PMIDs 20219977, 15191362, 11162489, 28903914), and two human studies that report no body composition at all — an acute metabolic challenge in ten men, five of them the fed arm (PMID 11158013) and an oral-priming GH-response study in seven women aged 65–82 (PMID 7952160). ipamorelin[tiab] AND (muscle[tiab] OR strength[tiab] OR "body composition"[tiab] OR lean[tiab]) returns 7: five reviews and primers (PMIDs 42578445, 42160466, 41880199, 41476424, 32257855) and two rat experiments (PMIDs 27186127, 11735244). Both also appear in a validated anti-doping assay covering nine growth-hormone-releasing peptides, with detection limits of 2–10 pg/mL (Thomas et al., PMID 22901302).

What the data do not show

Nothing here shows GHRP-6 or ipamorelin increasing lean mass in a person, because no indexed human study measured that. This page does not carry the rat tetanic-tension result across to people, does not treat a raised IGF-1 as a body-composition outcome, and does not present a missed primary endpoint as a near miss — 25.3 against 32.6 hours at p = 0.15 is a null result in 114 patients.

What the record does support is narrower: both compounds are credible laboratory tools, GHRP-6 with an established place in GH testing and ipamorelin with a documented selectivity for GH release over cortisol. A 2020 review of secretagogues in hypogonadal men calls the clinical data a “paucity” that limits understanding of their role (Sinha et al., PMID 32257855). The body-composition literature around them is mouse and rat work, and where it has been measured in humans it has not pointed the way the marketing does.

Sourcing note

Internal links for the SEO Specialist to confirm: the growth hormone in older adults page and the sleep and GH axis page.

Research use only. This page describes published human and animal literature. It is not medical advice, not a treatment recommendation, and not a suggestion for human use. Nothing we supply is for human or veterinary use.